Pharma BD Deal Intelligence

Merck & Co. Inc. / Organon & Co.

2007 · Acquisition/Merger · $14.4B · Complete

Women health assets cycled through three owners before 2021 Organon spinoff at $9B

Top 25 largest deals of the 2000s

Ranks computed across 828 graded deals (Critic + Outcome Score both present).

Write a proper summary of the 2007 ~$14.4B all-cash acquisition of Organon BioSciences N.V. from Akzo Nobel (with the buyer-attribution caveat below).

Key facts

Announced Nov 01, 2007
Closed Nov 01, 2007
Deal value $14.4B
Deal type Acquisition/Merger
Therapeutic area Cardiovascular, Dermatology, Immunology, Metabolic, Neurology, Oncology, Respiratory, Women's Health

Related deals — scored

Deal	Year	Value	Outcome
Merck & Co. Inc. / Organon & Co. (this deal)	2007	$14.4B	48
Merck & Co. Inc. / Acceleron Pharma Inc.	2021	$11.5B	90
Merck & Co. Inc. / Peloton Therapeutics Inc.	2019	$2.2B	88
Merck & Co. Inc. / AstraZeneca PLC	2017	$8.5B	87
Merck & Co. Inc. / Moderna, Inc.	2022	$250M	86
Merck & Co. Inc. / Moderna, Inc.	2016	$250M	84
Merck & Co. Inc. / Eisai Co., Ltd.	2018	$5.8B	83

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals

More: 2007 deals · Merck & Co. Inc. deals · Cardiovascular deals